Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity.…
We KEY on strength. Franchise leader. $LLY nice. #missionwinners #investing https://t.co/pufzIUO5ja
$LLY VERY nice. Leading group. Leading stock in that group. That is our "edge." #missionwinners #investing https://t.co/cfXuLO8ho3
Incredible strength by $LLY $BRK.B $UNH https://t.co/1cUUROWKxY
Watching price action helps a lot - not in a hurry to trade helps you see things Example: RED days money flows in to $LLY and when market green this $LLY goes RED
Maybe what this market needs is a cured war vaccine from $LLY https://t.co/WCRSN2YT43 https://t.co/6m58T0R9B4
$LLY article looking at its role in the ecosystem. Give it a read below https://t.co/Z95ULu8myo
30 analysts rate LLY Buy on consensus.
Consensus price target: $1,331.55 (+1.9% upside from $1,306.69)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Jonsson Patrik EVP & President, LLY Int'l | Aug 17, 2026 | Sale | 6,500 | $7.64M |
| Zakrowski Donald A SVP, Finance, & CAO | Aug 10, 2026 | Sale | 2,000 | $2.37M |
| Yuffa Ilya EVP&Pres, LLY USA&Global Capab | Jun 10, 2026 | Sale | 2,500 | $2.88M |
| LILLY ENDOWMENT INC other: Former 10% Shareholder | May 6, 2026 | Sale | 13,620 | $13.55M |
| LILLY ENDOWMENT INC other: Former 10% Shareholder | May 6, 2026 | Sale | 2,208 | $2.2M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $65.18B | +44.7% | $20.64B |
| 2024 | $45.04B | +32% | $10.59B |
| 2023 | $34.12B | +19.56% | $5.24B |
Stock data for LLY: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics